G6PC1 and fatty liver disease: Improved glucose tolerance and insulin signaling and did not develop fatty liver disease. Treatment also reduced plasma insulin, leptin, resistin, cholesterol, interleukin (IL)-1β, tumor necrosis factor alpha (TNF-α), and lowered hepatic glucose-6-phosphatase expression